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Abstract
Background: Cognitive deterioration is a core symptom of many neuropsychiatric disorders and target of
increasing significance for novel treatment strategies. Hence, its reliable capture in long-term follow-up studies is
prerequisite for recording the natural course of diseases and for estimating potential benefits of therapeutic
interventions. Since repeated neuropsychological testing is required for respective longitudinal study designs,
occurrence, time pattern and magnitude of practice effects on cognition have to be understood first under healthy
good-performance conditions to enable design optimization and result interpretation in disease trials.
Methods: Healthy adults (N = 36; 47.3 ± 12.0 years; mean IQ 127.0 ± 14.1; 58% males) completed 7 testing
sessions, distributed asymmetrically from high to low frequency, over 1 year (baseline, weeks 2-3, 6, 9, months 3, 6,
12). The neuropsychological test battery covered 6 major cognitive domains by several well-established tests each.
Results: Most tests exhibited a similar pattern upon repetition: (1) Clinically relevant practice effects during high-
frequency testing until month 3 (Cohen’s d 0.36-1.19), most pronounced early on, and (2) a performance plateau
thereafter upon low-frequency testing. Few tests were non-susceptible to practice or limited by ceiling effects.
Influence of confounding variables (age, IQ, personality) was minor.
Conclusions: Practice effects are prominent particularly in the early phase of high-frequency repetitive cognitive
testing of healthy well-performing subjects. An optimal combination and timing of tests, as extractable from this
study, will aid in controlling their impact. Moreover, normative data for serial testing may now be collected to
assess normal learning curves as important comparative readout of pathological cognitive processes.
Background
Cognitive decline is a common feature of many neurop-
sychiatric diseases and among the strongest determi-
nants of real-world functioning and quality of life in
affected individuals [e.g. [1-4]]. Moreover, it poses enor-
mous and ever-increasing costs on the progressively
aging industrial societies.
Efficient treatment of cognitive impairment is urgently
needed but not yet available. Therapeutically addressing
cognitive outcome requires careful assessment based on
comprehensive neuropsychological examination of rele-
vant cognitive domains. Cognitive tests can be applied
cross-sectionally to obtain first diagnostic information
but solid clinical judgments as well as research require
longitudinal observation. In clinical neuropsychology,
serial test administration is essential for (1) monitoring
of disease progression and/or potential recovery, or (2)
evaluating efficacy of a therapeutic agent or other inter-
ventions (e.g. rehabilitation programs) in both, rando-
mized clinical trials or clinical follow-up of single cases.
Dependent on the underlying questions, testing frequen-
cies have to be adapted to enable measurement of
short-term or long-term processes. With repeated test-
ing, however, the phenomenon of ‘practice effects’,
reflecting the capability of an individual to learn and
adjust, represents not only an additional important cog-
nitive readout but also an interfering variable complicat-
ing result interpretation [5-7].
Practice effects are defined as increase in a subject’s
test score from one administration to the next in the
absence of any interventions. Various reasons have been
discussed to explain practice-induced score gains, such
as reduced anxiety in or growing familiarity with the
testing environment, recall effects, improvement of
underlying functions, procedural learning, test
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Furthermore, practice effects seem to be influenced
by test (complexity, modality, alternate forms introduced
to make them ‘repeatable’) [9-17], or test-taker charac-
teristics (IQ, age, personality, mood, motivation)
[5,6,13,16,18-24], as well as intertrial interval [11,19,25].
Surprisingly, for most cognitive instruments, only test-
retest reliability coefficients, usually including not more
than 2 sessions, are available. Even the useful concept of
the ‘reliable change index’ corrected for practice and its
extensions [e.g. [26-29]] has not been systematically
integrated in most test manuals due to the low repeti-
tion rate of tests.
If not properly integrated into interpretation of cogni-
tive results, practice effects can easily lead to false con-
clusions: (1) degenerative processes obscured by practice
may be underestimated [30] or (2) treatment effects
m i g h tb eo v e r e s t i m a t e d ,p a r t i c u l a r l yi nt h ea b s e n c eo f
adequate control groups [31]. Even though the integra-
tion of appropriate control groups into clinical treatment
trials remains inevitable, a solid prediction of expected
practice effects under healthy good-performance condi-
tions is deemed essential for accurate effect size estima-
tion and selection of a suitable test set. In a single case
follow-up, this may actually be the only reasonable basis
of judgment. Therefore, it is surprising that despite a
number of pivotal prior studies dealing with practice
effects, comprehensive characteristics of normal perfor-
mance over time are not available. Specifically, the
impact of practice effects on frequent repetitive neurop-
sychological testing over as long as 1 year, comprising all
major cognitive domains, has not been systematically stu-
died in healthy well-performing individuals.
The first objective of the present study has been to
start filling this gap by exploring test-specific practice
effects on performance in the 6 major cognitive domains
upon repetitive testing of healthy subjects over a whole
year. The design of intertest intervals has been chosen
to meet typical requirements of neuroprotective trials,
with short-term high-frequency followed by long-term
low-frequency testing. As the second objective, recom-
mendations should be extractable from the findings of
the present work to design an optimal neuropsychologi-
cal testing procedure for future longitudinal clinical
research or routine. Finally, the third objective has been
to provide the ground for future collection of normative
data on longitudinal learning curves as an important but
thus far largely ignored diagnostic readout of cognitive
abilities.
Methods
Participants
The present study was approved by the local ethical
committee (Ethikkommission der Medizinischen
Fakultät der Georg-August-Universität Göttingen). All
study participants gave written informed consent after
complete description of the study. Native German
speaking healthy subjects were recruited via public
advertising and financially compensated upon comple-
tion of all follow-up sessions. (In our experience, finan-
cial compensation increases motivation of subjects to
keep the appointments but is highly unlikely to influ-
ence cognitive performance itself.) A total of 36 healthy
individuals (21 males and 15 females) with a mean age
of 47.3 ± 12.0 years (range 24-69 years) at study entry
participated. Prior to enrolment, a standardized, semi-
structured interview and a physical screening examina-
tion confirmed that subjects were free of significant
medical conditions or neuropsychiatric diseases (past or
current). Psychopathological ratings (Hamilton Rating
Scale for Depression, HAMD [32], mean 2.1 ± 2.9; Posi-
tive and Negative Syndrome Scale, PANSS [33], mean
32.3 ± 3.5) further ascertained a healthy sample with an
overall high intellectual level of performance as under-
lined by premorbid (mean 124.2 ± 12.8) and status intel-
ligence (mean 127.0 ± 14.1) quotients. Additionally, a
personality questionnaire (revised NEO Personality
Inventory, NEO-PI-R [34]) yielded results in the middle
normal range (mean Tv a l u e sfor personality factors:
Neuroticism 46.3 ± 9.3; Extraversion 51.7 ± 10.7; Open-
ness 52.2 ± 9.3; Agreeableness 53.4 ± 8.3; Conscien-
tiousness 50.6 ± 8.3). Exclusion criteria comprised use
of illicit and prescribed psychoactive drugs as well as
nicotine. Urine drug screening (testing for ethanol, can-
nabinoids, benzodiazepines and cocaine) at baseline and
unheralded repeat screens at random intervals verified
the drug-free state of all individuals.
Study design
All screened and included subjects underwent compre-
hensive neuropsychological and psychopathological test-
ings of approximately 2h duration under standardized
conditions (fixed sequence, fixed day time per subject)
on 7 occasions in total. The entire study was performed
by 2 examiners (trained psychologists). Tests were admi-
nistered according to standard instructions and, if avail-
able, alternate forms were used (for overview see
Additional file 1). The longitudinal study design com-
prised a short-term high-frequency testing phase with a
3-week intertest interval (baseline, week 2-3, week 6,
week 9 and month 3) and a long-term low-frequency
testing phase (months 6 and 12), amounting to a total
duration of 1 year per individual (Figure 1). The ratio-
nale of this testing schedule is derived from neuropro-
tective treatment trials on cognitive outcomes [e.g. [35]].
All included subjects completed all 7 testing sessions as
scheduled (no drop outs), resulting in a complete data
set without any missing data.
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Page 2 of 12Neuropsychological test battery
A total of 25 tests were selected to cover major cogni-
tive domains: (1) attention: Trail Making Test - part A
(TMT A [36]), Repeatable Battery for the Assessment of
Neuropsychological Status (RBANS [37]) subtests Cod-
ing and Digit Span, Test for Attentional Performance
(TAP [38]) subtests Visual Scanning and Alertness; (2)
learning and memory: RBANS subtests Figure Recall,
List Learning, List Recall, List Recognition, Story Mem-
ory, Story Recall; (3) executive functions: Trail Making
Test - part B (TMT B [36]), Wisconsin Card Sorting
Test - 64 Card Version (WCST-64 [39]), TAP subtests
Flexibility and Working Memory, Wechsler Memory
Scale - 3
rd edition (WMS-III [40]) subtest Letter Num-
ber Sequencing, Regensburger Wortschatztest (RWT
[41]) subtest phonemic verbal fluency; (4) motor func-
tions: 9-Hole Peg Test [42], Purdue Pegboard Test [43],
MacQuarrie Test for Mechanical Ability [44] subtests
Tapping and Dotting; (5) language:R B A N Ss u b t e s t s
Picture Naming and Semantic Fluency; and (6) visuos-
patial functions: RBANS subtests Lines and Figure
Copy. All listed tests are well-established and have been
described in detail as referenced (for a short description
see Additional file 1). Of all tests, only the most relevant
parameter is presented to avoid overrepresentation of
one test. To minimize expected strong recall effects,
RBANS short- and long-term memory tests, visuospatial
and language functions as well as the WCST-64 have
been performed less frequently (baseline, week 6,
months 3, 6, 12). Intelligence [premorbid intelligence
(Mehrfachwahl-Wortschatz-Intelligenz-Test, MWT-B
[45]) and state intelligence (revised German version of
the Wechsler Adult Intelligence Scale, short version,
H A W I E - R[ 4 6 ] ) ]-a sw e l la sp e r s o n a l i t y( N E O - P I - R )
measures were performed only at baseline to explore
their potential influence on the course of cognitive per-
formance. Current psychopathological symptoms
(HAMD, PANSS [32,33]) and quality of life (visual
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Figure 1 Study design comprising a comprehensive cross-sectional baseline evaluation and 2 longitudinal phases with high-frequency
followed by low-frequency testing. With a semi-structured interview, sociodemographic variables and medical history were collected. Drug
screening: Urine samples of all subjects were tested for ethanol, cannabinoids, benzodiazepines and cocaine at baseline, and tests were repeated
randomly afterwards. MWT-B, Mehrfachwahl-Wortschatz-Intelligenz-Test (premorbid intelligence measure); HAWIE-R, revised German version of
the Wechsler Adult Intelligence Scale (subtests Information, Similarities, Picture Completion, Block Design); NEO-PI-R, revised NEO Personality
Inventory; QoL, quality of life visual-analogue scale; PANSS, Positive and Negative Syndrome Scale; HAMD, Hamilton Rating Scale for Depression;
MacQuarrie; MacQuarrie Tapping and Dotting tests; Purdue Pegboard, Purdue Pegboard Test, TAP, Test for Attentional Performance (subtests
Alertness, Visual Scanning, Working Memory, Flexibility); TMT, Trail Making Test (A and B); WMS-III, Wechsler Memory Scale - 3
rd edition (subtest
Letter Number Sequencing); RWT, Regensburger Wortflüssigkeitstest (subtest phonemic verbal fluency); RBANS, Repeatable Battery for the
Assessment of Neuropsychological Status (Full Scale, complete RBANS performed; Attention, RBANS Attention subtests only); WCST-64, Wisconsin
Card Sorting Test - 64 Card Version.
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Page 3 of 12analogue scale ranging from 0-10) were assessed at each
testing time-point (Figure 1) to control for their poten-
tially fluctuating nature.
Statistical analysis
All numerical results are presented as mean ± SD in
text/table and mean ± SEM in figures. Statistical tests
were two-tailed for all analyses with a conservative sig-
nificance level at p < 0.01 to account for multiple statis-
tical testing (p < 0.05 was considered only marginally
significant). Analysis of variance (ANOVA) for repeated
measures with time as independent variable was applied
to all individual cognitive tests in order to investigate
significance of score changes over time (practice effects).
For analysis of cognitive domains, data of all single cog-
nitive tests (always expressed as % individual baseline of
the respective test) were combined to yield respective
super-ordinate cognitive mean curves. Two sets of
ANOVAs were calculated examining performance
changes during (1) the high-frequency testing phase,
including all testing time-points from baseline to month
3; and (2) the low-frequency testing phase, including
all testing time-points from month 3 to 12. Only if
differences over time reached significance, effect
sizes (Cohen’s d [47]) were calculated as d =( μtime-point
n-μbaseline)/spooled for determination of the clinical rele-
vance of practice effects. Thus, improvement in speed
tests (i.e. reduction in reaction time) or reduction in
error rate (WCST-64) resulted in negative effect sizes.
For consistency, these negative effect sizes were inverted
to express enhanced test performance as positive
Cohen’s d.A l t o g e t h e r ,d = 0.20-0.49 was considered to
represent small, d = 0.50-0.79 moderate and d ≥ 0.80
large effects [47]. To detect potential confounders of
cognitive performance, Pearson’sc o r r e l a t i o n sw e r ec a l -
culated between age, IQ (MWT-B or HAWIE-R IQ), all
5 NEO-PI-R personality factors, HAMD, PANSS total
scores and single cognitive measures at baseline. The
influence on the course of cognitive performance was
further explored using repeated-measures analyses of
covariance (ANCOVA) with time as independent vari-
able (baseline to month 12), and the respective potential
confounder as covariate. All analyses (Pearson’sc o r r e l a -
tions, repeated-measures ANOVAs and ANCOVAs)
were carried out using SPSS 17.0.
Results
Significance and clinical relevance of practice effects by
test and cognitive domain: main effect of time in
repeated-measures ANOVA and Cohen’s d
Descriptive statistics for all cognitive tests at all 7 time-
points are presented in Table 1. Expectedly, repeated-
measures ANOVA across the first 5 sessions of the
high-frequency testing phase revealed highly significant
score increases over time in the vast majority of tests
(practice effects in 17 of 25 tests; all p ≤ 0.006), with the
exception of TAP Alertness and Working Memory,
RBANS subtests Digit Span, List Recognition, Semantic
Fluency, Lines, Figure Copy, and MacQuarrie Dotting.
Even after a most conservative Bonferroni correction for
25 comparisons, resulting in an adjusted alpha of 0.002,
the significance of results is preserved, with the excep-
tion of TMT A and WCST-64 (both p = 0.006).
To estimate the magnitude of the observed significant
practice effects, most prominent from baseline to month
3, the Cohen’s d statistic of each test and cognitive
domain was calculated for comparison baseline - month
3 (Table 1, hierarchical listing of tests per domain
according to effect sizes). Effect sizes of the high-
frequency testing phase (baseline - month 3) are mainly
within the range of moderate effects (d = 0.51-0.75) and
congruent with repeated-measures ANOVA results. A
domain-wise comparison of effect sizes demonstrates a
homogenous pattern in all cognitive domains (mainly
moderate effects) except for attentional functions (high
variance with small to large effect sizes).
Upon long intertest intervals after month 3 until study
end (month 12) no significant performance changes
could be found in 23 of 25 tests, i.e. performance levels
acquired by high-frequency testing remained stable and
did not return to baseline values. Only one test, RWT
phonemic verbal fluency, showed further enhanced test
scores (p < 0.001). A ceiling effect in RBANS Picture
Naming during high- and low-frequency testing phase
artificially produced significant results (Table 1).
The longitudinal course of performance in all 6 cogni-
tive domains (data of single tests were combined to
yield respective super-ordinate cognitive categories) is
illustrated in Figure 2. ANOVAs conducted on this data
confirmed the time pattern of single test comparisons:
Strong practice effects upon high-frequency testing and
a plateau held with decreasing frequency. Regarding
cognitive domains, the most pronounced changes occur
until month 3 in executive functions (14.0 ± 10.7%), fol-
lowed by learning/memory (13.3 ± 12.3%) and attention
(11.9 ± 10.6%) (Figure 2).
Improvement from baseline to second testing accounts
for the largest proportion of change in all cognitive
domains (Figure 3). Accordingly, for most tests, Cohen’s
d was highest for baseline - week 2-3 interval (d = 0.30-
0.55 for domains, d = 0.22-0.71 for single tests). In
contrast, Cohen’s d, if calculated for the late between-
assessment intervals, i.e. from month 3 to 6 or 12,
would show mainly ‘no effect’ (exceptions: d =0 . 2 8f o r
RWT phonemic verbal fluency and d = 0.50 for RBANS
Picture Naming).
To address the important question of ceiling effects, the
proportion of subjects reaching a defined performance
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Page 4 of 12Table 1 Neuropsychological follow-up data (N = 36)
ANOVA for repeated measures
Baseline Week 2-3 Week 6 Week 9 Month 3 Month 6 Month 12
Test parameter Mean SD Mean SD Mean SD Mean SD Mean SD F4.32
§ p1 d Mean SD Mean SD F2.34 p2
ATTENTION 0.69
‡
TAP Visual Scanning - critical trials 2401.0 604.8 2041.4 550.1 1908.2 519.9 1782.3 519.4 1712.0 550.1 14.64 <.001 1.19 1782.3 555.8 1728.8 548.6 2.57 .09
Trail Making Test - part A 29.3 10.7 24.9 9.0 24.5 8.9 22.8 8.6 23.3 12.0 4.43 .006 0.53 22.8 8.2 23.4 7.0 0.44 .65
RBANS Coding 51.6 9.6 56.0 10.6 52.2 9.0 54.5 9.7 55.1 10.0 9.74 <.001 0.36 54.8 10.3 54.9 8.8 0.05 .95
TAP Alertness - with cue sound 265.8 44.8 262.8 60.3 261.9 54.8 258.8 65.9 248.9 64.8 2.39 .07 - 254.4 46.7 264.0 70.3 1.89 .17
RBANS Digit Span 10.8 2.1 10.3 1.8 10.9 1.9 10.8 2.4 10.7 2.0 1.00 .42 - 11.1 2.2 11.3 1.9 2.27 .12
LEARNING AND MEMORY 0.67
‡
RBANS Figure Recall 16.6 2.9 - - 18.4 2.1 - - 18.4 1.8 11.65 <.001 0.75 18.8 1.3 18.6 1.6 0.57 .57
RBANS List Recall 7.1 2.2 - - 7.9 2.0 - - 8.4 1.6 13.28 <.001 0.68 8.9 1.4 8.4 1.7 2.33 .11
RBANS List Learning 31.3 3.6 - - 32.7 4.5 - - 33.8 3.7 9.05 .001 0.68 34.8 3.6 33.7 3.7 2.05 .14
RBANS Story Memory 18.1 4.1 - - 18.3 3.5 - - 20.5 2.8 16.74 <.001 0.68 19.8 3.3 19.9 3.7 1.56 .22
RBANS Story Recall 9.6 1.9 - - 9.2 1.7 - - 10.5 1.4 15.79 <.001 0.54 9.9 1.9 10.4 1.6 2.50 .10
RBANS List Recognition 19.8 0.5 - - 19.7 0.6 - - 19.7 0.8 0.54 .59 - 19.7 0.6 19.7 0.7 0.07 .93
EXECUTIVE FUNCTIONS 0.50
‡
Trail Making Test - part B 70.1 28.5 61.4 29.9 59.7 29.1 52.5 19.5 50.6 22.9 11.68 <.001 0.75 54.8 26.9 53.7 23.7 0.88 .42
WCST-64 - perseverative errors 9.2 4.8 - - 7.4 5.0 - - 6.6 4.2 6.00 .006 0.58 6.3 4.8 7.2 5.3 0.59 .56
TAP Flexibility 858.9 320.8 783.6 351.8 750.3 325.8 698.0 332.9 697.9 329.9 7.46 <.001 0.49 685.7 345.7 682.0 305.6 0.32 .73
WMS-III Letter Number Sequencing 11.4 2.5 12.3 2.3 12.2 2.3 12.6 2.8 12.7 3.0 6.30 .001 0.47 12.9 2.7 12.9 2.9 0.19 .83
RWT phonemic verbal fluency 53.6 14.0 60.0 18.0 60.3 16.6 62.8 15.2 56.4 16.1 10.55 <.001 0.19* 61.2 18.2 63.8 18.3 16.38 <.001
TAP Working Memory 568.3 160.4 547.7 144.7 569.6 155.7 565.6 176.5 533.0 150.4 1.55 .21 - 528.3 161.0 533.3 139.3 0.06 .94
MOTOR FUNCTIONS 0.56
‡
9-Hole Peg Test - dominant hand 18.1 2.5 17.4 2.1 16.8 2.4 16.7 2.2 16.5 2.4 7.11 <.001 0.65 16.4 2.3 16.2 2.0 1.29 .29
Purdue Pegboard Test - assembly 32.4 8.2 33.6 8.5 34.1 8.0 35.0 8.4 36.7 8.3 8.82 <.001 0.52 35.8 9.2 35.5 9.4 1.70 .20
MacQuarrie Tapping 39.2 7.5 41.4 7.0 41.5 7.8 43.0 8.2 43.1 7.7 13.08 <.001 0.51 42.5 8.2 42.3 7.7 1.93 .16
MacQuarrie Dotting 66.3 12.4 70.0 12.1 69.8 12.3 70.1 11.1 71.2 10.3 2.21 .09 - 71.2 12.0 69.5 12.7 1.86 .17
LANGUAGE 0.00
‡
RBANS Picture Naming 10.0 0.0 - - 9.7 0.5 - - 10.0 0.2 7.76 .002 0.00* 9.8 0.4 10.0 0.0 4.86 .01
RBANS Semantic Fluency 23.2 5.2 - - 25.0 4.8 - - 24.4 4.5 2.41 .11 - 25.0 5.2 23.5 5.4 1.62 .21
VISUOSPATIAL FUNCTIONS -
‡
RBANS Lines 18.1 2.8 - - 18.5 2.0 - - 18.7 1.5 1.00 .38 - 18.6 1.4 19.0 1.8 1.23 .30
RBANS Figure Copy 19.9 0.4 - - 19.9 0.4 - - 19.9 0.2 0.50 .61 - 19.9 0.4 19.8 0.4 1.33 .28
Significant ANOVA (analysis of variance) time effects bolded.
§In case of only 3 testings until month 3, df = 2.34. p1 displays significance from baseline to month 3; p2 denotes significance from month 3 to month 12. Cohen’s
d =( μmonth 3 - μbaseline)/spooled with d = 0.20-0.49 denoting small, d = 0.50-0.79 moderate, and d ≥ 0.80 large effect sizes. *indicates d < 0.20, i.e. “no effect”. Effect sizes presented only if respective differences over time are
significant (p < 0.01).
‡Cohen’s d for cognitive domains expressed as mean of single-test effect sizes of the respective cognitive domain.
TAP, Test for Attentional Performance; RBANS, Repeatable Battery for the Assessment of Neuropsychological Status; WCST-64, Wisconsin Card Sorting Test - 64 Card Version; WMS-III, Wechsler Memory Scale - 3
rd
edition; RWT, Regensburger Wortflüssigkeitstest.
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Figure 2 Pattern of practice effects in cognitive domains over time. Data of all single tests (always expressed as % individual baseline of the
respective test), representing one particular cognitive domain, were combined to yield respective super-ordinate cognitive mean curves. In
almost all cognitive domains, changes in total test scores over time exhibit a similar practice pattern: significant improvement during the high-
frequency testing phase and stabilization of performance during the low-frequency testing phase. Most pronounced score increases are seen in
executive functions as well as in learning and memory, whereas changes in visuospatial performance fail to reach significance. Significance refers
to a main effect of time determined with ANOVA for repeated measures, including all testing time-points from baseline to month 3, or from
month 3 to month 12, respectively. Mean ± SEM given. ***p < 0.001; *p < 0.05; n.s., not significant.
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Figure 3 Distribution of practice effects: Changes from one testing to the next. All cognitive domains (respective single tests grouped as
described in Figure 2) show most pronounced improvement in performance from baseline to the 2
nd testing time-point. At late testing time-
points with long intertest intervals (5
th to 6
th, and 6
th to 7
th testing), test scores show a slight tendency to decrease. Mean of % change given.
Lines indicate logarithmic trends.
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Figure 4 Magnitude of practice effects: development of clinical classification over 1 year. Clinical classification of baseline performance
shows that cognitive performance is distributed across all categories (below- to above-average percentile ranks, PR) despite a high-IQ sample of
healthy individuals. In all depicted cognitive domains, score gains lead to better clinical classification over time (selected time-points months 3
and 12 presented) without reaching upper limits for most subjects. Only in visuospatial functions, the majority of subjects achieved highest
scores already at baseline with only modest subsequent changes, altogether pointing to a ceiling effect. Clinical classifications of individual
performance are based on test-specific normative data and averaged by cognitive domains. For executive functions, normative data of RWT
phonemic verbal fluency is unavailable. Data on motor tests are not presented due to insufficient normative data.
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(Figure 4; clinical classifications based on test-specific nor-
mative data). For all cognitive domains, changes of clinical
classification over time still exclude ceiling effects except
for visuospatial functions.
Control of potentially confounding factors: Pearson’s
correlations at baseline and ANCOVAs on course of
cognitive performance up to month 12
Age
Since consistently significant correlations between age
and cognitive baseline values in most tests with a speed
component were found, age was implemented as a cov-
ariate in repeated-measures ANCOVA for all cognitive
tests. Only for TAP flexibility, a significant time x age
interaction effect could be shown (F = 3.43; p = 0.01),
whereas all other learning curves were not influenced by
age.
Intelligence
Neither MWT-B premorbid IQ nor HAWIE-R full scale
IQ correlated systematically with cognitive test scores at
baseline (only MWT-B IQ - RWT phonemic verbal flu-
e n c y :r=- 0 . 4 7 ,p=0 . 0 0 4 ;H A W I E - RI Q-T M TA :r=
-0.42, p = 0.01; HAWIE-R IQ - RBANS Figure Copy: r
= 0.57, p < 0.001). Accordingly, IQ did not mediate the
course of cognitive performance except for RBANS Fig-
u r eC o p y( t i m exH A W I E - RI Q interaction F = 5.87; p
= 0.001). These findings are most likely due to the high
and homogenous IQ of our sample (mean MWT-B IQ:
124.2 ± 12.8, mean HAWIE-R IQ: 127.0 ± 14.1).
Personality
Explorative correlational analyses of each NEO-PI-R
personality factor with each cognitive test at baseline
revealed only isolated significance for Agreeableness -
MacQuarrie Tapping and Dotting (r = -.041, p = 0.01
for both) and Conscientiousness - RBANS Story Mem-
ory (r = -0.41, p = 0.01). Also, none of the 5 personality
factors consistently influenced practice effects (only
interaction time x Agreeableness F = 5.17; p = 0.001 for
RBANS Coding).
Psychopathological symptoms and quality of life
As expected in a sample of healthy volunteers, HAMD
and PANSS scores were low and showed small variance
(‘floor effect’ - see description of subjects). Only 3 signif-
icant correlations with cognition could be determined at
baseline: HAMD - TAP Flexibility (r = 0.47, p = 0.004)
HAMD - TMT A (r = 0.53, p = 0.001), PANSS - TMT
A (r = 0.42, p = 0.01). Over the study period, HAMD
remained unchanged (2.1 ± 2.9 to 2.6 ± 2.8; F = 0.545, p
= 0.77), and PANSS scores increased marginally from
baseline to month 12 (32.3 ± 3.5 to 33.0 ± 3.5, F = 4.97,
p = 0.001) but never reached a pathological level, i.e. is
clinically irrelevant. A similar pattern was obtained for
QoL and cognition: QoL stayed stable over time and
yielded only 2 significant and counter-intuitive correla-
tions with cognitive tests at baseline (QoL - RBANS
Digit Span: r = -0.42, p = 0.01, QoL - WMS-III Letter
Number Sequencing: r = 0.43, p = 0.01).
Taken together, the evaluation of potential modulators
of cognitive performance and practice effects (age, IQ,
personality factors, QoL, degree of depression and psy-
chopathology) revealed only isolated findings with single
cognitive tests at baseline (20 significant of 275 correla-
tions) or the course of cognitive performance (only
3 significant time x covariate interactions of 200 ANCO-
VAs). Using a conservative approach of alpha adjust-
ment for multiple testing, these isolated findings even
disappear. Thus, none of the analyses (Pearson’s correla-
tions, repeated-measures ANCOVAs) suggest that the
cognitive performance pattern was due to pre-existing
intellectual, personality, sociodemographic or to current
psychopathological differences that systematically
affected the slope of practice effects. All before men-
tioned data on cognition is therefore presented without
any of the explored covariates.
Discussion
In the present study, we provide for the first time com-
prehensive data on clinically relevant practice effects in
healthy well-performing subjects over a 1-year period of
frequent repetitive testing across 6 distinct cognitive
domains. During the initial phase of high-frequency test-
ing for 3 months, strong practice effects occur early on,
most prominent in executive functions and learning/
memory. After 3 months and upon reduced testing fre-
quency, a stabilization/plateau of the acquired cognitive
level until study end is observed. Age, intellectual capa-
city, personality features, or psychopathological scores
have no consistent influence on the course of cognitive
performance.
Generally, comparisons between the present and pre-
vious studies are confounded by different designs,
including the use of diverse cognitive tests, fewer repeti-
tions, and/or varying intertest intervals. The finding that
strongest changes in performance occur from baseline
to the second testing, however, complies well with a
number of similar results on distribution of practice
effects [10,12,15,17,18,48]. The extent of practice effects
observed here even exceeds effect sizes described by
Hausknecht et al [10] (d = 0.26) or Bird et al [20], using
comparable intervals.
In contrast to previous studies, showing a similar magni-
tude of practice effects short-term [9,12,48], our longitudi-
nal design addresses particular needs of neuroprotective/
neuroregenerative treatment trials, including both, a prac-
tice and a retention phase. Just McCaffrey et al [25] had a
somewhat related long-term design, but only 4 sessions in
total (baseline, week 2, months 3 and 6), with the last
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Page 9 of 12testing at month 6, and a much shorter test battery. The
essential findings of this study are in agreement with the
respective parts of the present work. Another study worth
mentioning here, provided useful information about prac-
tice-dependent test selection to build on, but used only a
high-frequency testing schedule (20 sessions in 4 weeks)
without long-term follow-up and without change in test-
ing frequency [49].
Regarding the different cognitive domains, executive
functions showed highest score increases over time, fol-
lowed by learning and memory. For executive functions,
results of other studies are contradictory [e.g.
[17,20,50]], ranging from no over small to strong prac-
tice effects. The strong practice effects in almost all
executive functions found here are most likely the result
of a higher repetition rate (as compared to [20,50]) or
the use of less alternate forms (as compared to [17]). In
line with our findings, there is wide agreement that
memory functions benefit most from practice
[7,25,48,51] and are evident even when alternate test
forms are applied [10,14,15,17,52]. Since parallel forms
were also administered in the present study, and the
respective tests were reduced to 4 repetitions, test
sophistication [8] as well as improvement of the under-
lying functions rather than simple recall effects may
have contributed to improved performance.
On the basis of single test characteristics and results
over time, no prediction can be made regarding the
impact of repetitive testing. Practice effects seem to be
unrelated to task complexity or modality. On the other
hand, the present work provides more than test-specific
information: cognitive domains, assessed with an exten-
sive test battery, covering each domain by several tests,
revealed very homogenous effect sizes within one
domain, i.e. similar practice effects irrespective of the test
used, pointing to genuine change in the underlying target
domain (transfer effects). Only within the attention
domain, highly varying effect sizes of individual tests may
indicate respective test specificity [53], e.g. in our study
TAP Visual Scanning displayed largest practice effects
whereas RBANS Digit Span revealed no effects. In the
overall picture of transfer effects, the few tests with ceil-
ing effects did not play a role in this respect.
Logically, our findings on practice effects raise the
question whether after 3 months of regular practice the
maximally possible improvement is already achieved or
whether continued practice would lead to an even more
enhanced performance. Even though this was not the
objective of the present study, it would be interesting to
investigate how many additional sessions within the
high-frequency period are required until the individual
upper performance limit is reached.
Although the majority of tests showed considerable
practice effects, at least one test in most of the cognitive
domains was found resistant to practice. Again, task com-
plexity does not seem to be the underlying factor explain-
ing resistance. For more ‘deficit-oriented’ subtests like
RBANS List Recognition, Lines and Figure Copy, ceiling
effects (expected especially in high IQ subjects) did not
allow further improvement of test scores. For most other
tests this was not the case since the majority of subjects,
despite high IQ, did not score at above-
average. Nevertheless, the high IQ level of our sample may
have contributed to the observed strong practice effects as
reported in studies showing that high IQ subjects benefit
more from prior test exposure (’the rich get richer’
[16,18]). This greater benefit of high IQ, however, is still
equivocal as is a potential influence of age [20,50]. In fact,
neither age nor IQ, applied as covariates, revealed a clear
effect in the present work. Also other covariates, i.e. per-
sonality and psychopathology ratings, failed to show any
appreciable impact on learning curves. The most plausible
explanation would be the fact that healthy volunteers
s c o r e di nav e r yr e s t r i c t e d‘normal’ range in these cate-
gories. Such restricted range holds similarly true for IQ.
The aim of the present study, apart from long-term
analysis of practice effects, was to provide recommenda-
tions for an ‘ideal’ neuropsychological test battery suita-
ble for serial testing in research and routine. As obvious
from our results, two major points have to be consid-
ered in this recommendation: test selection and timing.
Tests of first choice are those that are essentially resis-
tant to practice: TAP Alertness or RBANS Digit Span
for attention; TAP Working Memory for executive func-
tions; MacQuarrie Dotting for motor functions; RBANS
Semantic Fluency for language.
For learning and memory, no practice-resistant valid
test could be identified. Therefore, for evaluation of this
particular domain, a ‘dual baseline’ approach [5,6] is
suggested to partly cut off early practice effects: If the
most prominent improvement occurs from first to sec-
ond assessment, the second may serve as baseline for
subsequent assessments. For the domain learning and
memory, this applies to RBANS Figure Recall, List
Recall and List Learning.
As eventual alternatives for the above listed domain-
specific, practice-resistant tests, the dual baseline approach
may be used for TMT A, RBANS Coding (attention),
WCST-64, WMS-III Letter Number Sequencing, RWT
phonemic verbal fluency (executive functions) and Mac-
Quarrie Tapping (motor functions). Of all the explored
cognitive domains, only for visuospatial functions a valid
test recommendation cannot be made at this point.
The selection of tests for a neuropsychological battery
is often a matter of compromises and limitations. Due
to time restrictions and fatiguing effects, it is impossible
to completely cover all relevant cognitive domains with
all their facets in one session. For instance, in this
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interference resolution as important aspects of executive
function had to be omitted due to these restrictions. On
the other hand, some deficit-oriented tests, essential for
clinical studies, were selected that ultimately displayed
ceiling effects in the healthy sample. Especially for the
domains visuospatial functions and language, not only
more tests but also more suitable tests have to be identi-
fied and investigated longitudinally.
In addition to our recommendations for an optimal,
practice-resistant test battery, also our data of tests with
strongest practice effects are useful for future applica-
tions. Based on reliable change index calculations, hier-
archical linear modelling or regression models, it will
now be possible to discriminate whether performance
change of an individual or a group is clinically meaning-
ful or whether it simply reflects change due to the here
described practice effects.
Conclusions
Although the present study with its asymmetrical testing
design addresses particularly needs of neuroprotective
trials, the principal findings on practice effects also
apply to all kinds of clinical and non-clinical studies
with repetitive short- and long-term neuropsychological
testing. Based on the here reported results, an essentially
complete cognitive test battery covering all major cogni-
tive domains can be composed. This battery should be
largely resistant to practice or at least allow a valid esti-
mate of practice effects. Thus, true cognitive improve-
ment will be better discernible in healthy individuals
and even more so in patient populations with expectedly
reduced capabilities to learn [31,49,54,55]. Along these
lines, the collection of normative data for serial test
administration as important information on individual
longitudinal learning can now easily be initiated.
Additional material
Additional file 1: Detailed descriptive information on the
neuropsychological test battery. This file contains descriptive
information on the neuropsychological tests of the presented study
(underlying function, procedure) and an overview of alternate test
versions.
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